Bausch Health Companies Inc. (TSX:BHC)
Canada
· Delayed Price · Currency is CAD | Market Cap | 3.23B |
| Revenue (ttm) | 13.99B |
| Net Income (ttm) | -57.49M |
| Shares Out | n/a |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | 1.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 572,380 |
| Average Volume | 468,762 |
| Open | 8.85 |
| Previous Close | 8.74 |
| Day's Range | 8.75 - 9.29 |
| 52-Week Range | 5.45 - 13.74 |
| Beta | 0.28 |
| RSI | 72.19 |
| Earnings Date | Aug 7, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live bet...
A Billionaire Trump Supporter Is Buying These Two Stocks
John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.
Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares
Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.
Repricing Potential Driven By Deleveraging
Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended d...
Bausch Health ticks higher following large director stock purchase
Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma
The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appear...
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("An...
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bill Ackman Took A $4 Billion Hit But Says 'Making Progress Each Day' Was Key To Recovering From The Valeant Disaster
Billionaire investor Bill Ackman opened up about the most painful chapter of his career—the collapse of his $4 billion investment in Valeant Pharmaceuticals . In a candid interview, he explained how t...
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approv...
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing
Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ETCompany ParticipantsGaren Sarafian - IRThomas Appio -...
Bausch Health Companies Inc. 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Bausch Health Companies Inc.
Bausch Health Announces First Quarter 2025 Results
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies...
Bausch Health Companies Q1 2025 Earnings Preview
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)...
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4
Bausch Health Learns Icahn Has 34% Economic Interest in Shares
Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.
Bausch Health Learns Icahn Has 34% Economic Interest in Shares
Bausch Health says Carl Icahn has exposure to about 34% of company's shares
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.
Bausch Health jumps after Carl Icahn’s 34% stake
Bausch Health Announces Filing of Supplement to Proxy Statement
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 ...